vs

Side-by-side financial comparison of BANK OF HAWAII CORP (BOH) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

BANK OF HAWAII CORP is the larger business by last-quarter revenue ($192.3M vs $151.7M, roughly 1.3× Tarsus Pharmaceuticals, Inc.). BANK OF HAWAII CORP runs the higher net margin — 29.9% vs -5.5%, a 35.4% gap on every dollar of revenue. Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 10.7%).

The Bank of Hawaii Corporation is an American regional commercial bank headquartered in Honolulu, Hawaii. It is Hawaii's second oldest bank and its largest locally owned bank in that the majority of the voting stockholders reside within the state. Bank of Hawaii has the most accounts, customers, branches, and ATMs of any financial institution in the state. The bank consists of four business segments: retail banking, commercial banking, investment services, and treasury. The bank is currently ...

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

BOH vs TARS — Head-to-Head

Bigger by revenue
BOH
BOH
1.3× larger
BOH
$192.3M
$151.7M
TARS
Higher net margin
BOH
BOH
35.4% more per $
BOH
29.9%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
10.7%
BOH

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BOH
BOH
TARS
TARS
Revenue
$192.3M
$151.7M
Net Profit
$57.4M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
29.9%
-5.5%
Revenue YoY
128.4%
Net Profit YoY
30.6%
63.8%
EPS (diluted)
$1.30
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BOH
BOH
TARS
TARS
Q1 26
$192.3M
Q4 25
$189.6M
$151.7M
Q3 25
$182.6M
$118.7M
Q2 25
$174.5M
$102.7M
Q1 25
$169.9M
$78.3M
Q4 24
$163.2M
$66.4M
Q3 24
$162.7M
$48.1M
Q2 24
$156.9M
$40.8M
Net Profit
BOH
BOH
TARS
TARS
Q1 26
$57.4M
Q4 25
$60.9M
$-8.4M
Q3 25
$53.3M
$-12.6M
Q2 25
$47.6M
$-20.3M
Q1 25
$44.0M
$-25.1M
Q4 24
$39.2M
$-23.1M
Q3 24
$40.4M
$-23.4M
Q2 24
$34.1M
$-33.3M
Operating Margin
BOH
BOH
TARS
TARS
Q1 26
Q4 25
40.9%
-5.3%
Q3 25
37.1%
-12.2%
Q2 25
34.6%
-21.6%
Q1 25
33.1%
-33.5%
Q4 24
31.6%
-36.8%
Q3 24
32.3%
-52.3%
Q2 24
28.9%
-81.6%
Net Margin
BOH
BOH
TARS
TARS
Q1 26
29.9%
Q4 25
32.1%
-5.5%
Q3 25
29.2%
-10.6%
Q2 25
27.3%
-19.8%
Q1 25
25.9%
-32.1%
Q4 24
24.0%
-34.8%
Q3 24
24.8%
-48.7%
Q2 24
21.7%
-81.6%
EPS (diluted)
BOH
BOH
TARS
TARS
Q1 26
$1.30
Q4 25
$1.40
$-0.17
Q3 25
$1.20
$-0.30
Q2 25
$1.06
$-0.48
Q1 25
$0.97
$-0.64
Q4 24
$0.85
$-0.57
Q3 24
$0.93
$-0.61
Q2 24
$0.81
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BOH
BOH
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$3.3M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$1.9B
$343.4M
Total Assets
$23.9B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BOH
BOH
TARS
TARS
Q1 26
$3.3M
Q4 25
$946.5M
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$935.2M
$407.9M
Q4 24
$763.6M
$291.4M
Q3 24
$1.3B
$317.0M
Q2 24
$925.3M
$323.6M
Total Debt
BOH
BOH
TARS
TARS
Q1 26
Q4 25
$558.2M
$72.4M
Q3 25
$558.2M
$72.3M
Q2 25
$558.2M
$72.1M
Q1 25
$558.3M
$72.0M
Q4 24
$558.3M
$71.8M
Q3 24
$558.3M
$71.7M
Q2 24
$560.1M
$71.6M
Stockholders' Equity
BOH
BOH
TARS
TARS
Q1 26
$1.9B
Q4 25
$1.9B
$343.4M
Q3 25
$1.8B
$335.1M
Q2 25
$1.7B
$332.6M
Q1 25
$1.7B
$342.5M
Q4 24
$1.7B
$224.5M
Q3 24
$1.7B
$237.5M
Q2 24
$1.6B
$252.2M
Total Assets
BOH
BOH
TARS
TARS
Q1 26
$23.9B
Q4 25
$24.2B
$562.2M
Q3 25
$24.0B
$534.6M
Q2 25
$23.7B
$495.0M
Q1 25
$23.9B
$500.8M
Q4 24
$23.6B
$377.0M
Q3 24
$23.8B
$376.3M
Q2 24
$23.3B
$376.8M
Debt / Equity
BOH
BOH
TARS
TARS
Q1 26
Q4 25
0.30×
0.21×
Q3 25
0.31×
0.22×
Q2 25
0.32×
0.22×
Q1 25
0.33×
0.21×
Q4 24
0.33×
0.32×
Q3 24
0.34×
0.30×
Q2 24
0.35×
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BOH
BOH
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BOH
BOH
TARS
TARS
Q1 26
Q4 25
$218.3M
$19.3M
Q3 25
$38.5M
$18.3M
Q2 25
$81.7M
$-29.4M
Q1 25
$18.3M
$-20.7M
Q4 24
$170.9M
$-22.2M
Q3 24
$-20.3M
$-8.7M
Q2 24
$45.7M
$-14.4M
Free Cash Flow
BOH
BOH
TARS
TARS
Q1 26
Q4 25
$184.3M
$13.0M
Q3 25
$29.8M
$16.3M
Q2 25
$72.6M
$-30.4M
Q1 25
$10.2M
$-21.2M
Q4 24
$161.3M
$-22.3M
Q3 24
$-25.0M
$-8.9M
Q2 24
$40.7M
$-15.4M
FCF Margin
BOH
BOH
TARS
TARS
Q1 26
Q4 25
97.2%
8.6%
Q3 25
16.3%
13.8%
Q2 25
41.6%
-29.6%
Q1 25
6.0%
-27.1%
Q4 24
98.8%
-33.5%
Q3 24
-15.3%
-18.6%
Q2 24
26.0%
-37.8%
Capex Intensity
BOH
BOH
TARS
TARS
Q1 26
Q4 25
18.0%
4.2%
Q3 25
4.7%
1.6%
Q2 25
5.2%
1.0%
Q1 25
4.8%
0.8%
Q4 24
5.9%
0.1%
Q3 24
2.8%
0.6%
Q2 24
3.2%
2.5%
Cash Conversion
BOH
BOH
TARS
TARS
Q1 26
Q4 25
3.58×
Q3 25
0.72×
Q2 25
1.71×
Q1 25
0.42×
Q4 24
4.36×
Q3 24
-0.50×
Q2 24
1.34×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BOH
BOH

Net Interest Income$151.0M79%
Noninterest Income$41.3M21%

TARS
TARS

Segment breakdown not available.

Related Comparisons